NCT03931070View on ClinicalTrials.gov

The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU

PHASE4CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

February 1, 2022

Study Completion Date

February 1, 2022

Conditions
Delirium
Interventions
DRUG

Ramelteon

Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.

DRUG

Placebo - Cap

Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.

Trial Locations (1)

02903

Rhode Island Hospital, Providence

All Listed Sponsors
lead

Rhode Island Hospital

OTHER

NCT03931070 - The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU | Biotech Hunter | Biotech Hunter